This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Related Collections Related Articles

(Circulation. 2005;112:147.)
© 2005 American Heart Association, Inc.

Issue Highlights

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	EFFECT OF PRAVASTATIN ON RATE OF KIDNEY FUNCTION LOSS IN PEOPLE WITH OR AT RISK FOR CORONARY DISEASE, by Tonelli et al.

 
Renal dysfunction is an independent risk factor for cardiovascular disease and its associated complications. Prior studies have suggested that lipid-lowering medications may reduce the rate of loss of renal function. A group of investigators from three large pravastatin studies (CARE, LIPID, and WOSCOPS) combined their data from more than 18 thousand patients, followed up for 5 years, either with previous coronary events or at high risk of cardiovascular disease. In patients with moderate chronic kidney disease, pravastatin reduced the rate of loss of renal function by about 8% and also reduced the risk of acute renal failure. The mechanisms of benefit are unknown but may include the antiinflammatory effects of statins or reduction in renal atherosclerosis. Further studies will be needed to determine the effect of statins in patients with more severe renal dysfunction. See p 171.

	HEREDITARY HEMOCHROMATOSIS AND RISK OF ISCHEMIC HEART DISEASE: A PROSPECTIVE STUDY AND A CASE-CONTROL STUDY, by Ellervik et al.

 
The potential link between iron levels and the risk of coronary artery disease has been termed the "iron hypothesis." Some have speculated that the oxidation of iron produces free hydroxyl radicals, leading to more oxidized LDL particles and subsequent atherosclerosis. These investigators use hereditary hemochromatosis to study the effect of iron overload on risk of ischemic heart disease. They conducted a prospective study with long follow-up and a case-control study to investigate the association of specific hereditary hemochromatosis genotypes with the risk of ischemic heart disease. They also examined the relationship of these genotypes with oxidized LDL, transferrin saturation, and ferritin levels. Thus, the study provides insight about the overall association and . . . [Full Text of this Article]

Related Articles:

Management of Massive Pulmonary Embolism

Nils Kucher and Samuel Z. Goldhaber
Circulation 2005 112: e28-e32. [Extract] [Full Text]

Transient Occlusion of the Middle Cerebral Artery by Macroembolism During Carotid Stenting for Traumatic Dissection of the Common Carotid Artery

Eisuke Furui, Yoshikazu Okamoto, Shinya Kida, Junkoh Yamashita, Osamu Matsui, and Masahito Yamada
Circulation 2005 112: e33-e34. [Extract] [Full Text]

Integration of 3-Dimensional Cardiac Computed Tomography Images With Real-Time Electroanatomic Mapping to Guide Catheter Ablation of Atrial Fibrillation

Brad J. Mikaelian, Zachary J. Malchano, Petr Neuzil, Jiri Weichet, Shephal K. Doshi, Jeremy N. Ruskin, and Vivek Y. Reddy
Circulation 2005 112: e35-e36. [Extract] [Full Text]

Letter Regarding Article by Adamson et al, "Continuous Autonomic Assessment in Patients With Symptomatic Heart Failure: Prognostic Value of Heart Rate Variability Measured by an Implanted Cardiac Resynchronization Device" • Response

Satish R. Raj, Daniel E. Roach, Robert S. Sheldon, Philip B. Adamson, Andrew L. Smith, William T. Abraham, Karen J. Kleckner, Robert W. Stadler, and Melissa M. Rhodes
Circulation 2005 112: e37-e38. [Extract] [Full Text]

Hereditary Hemochromatosis and Risk of Ischemic Heart Disease: A Prospective Study and a Case-Control Study

Christina Ellervik, Anne Tybjærg-Hansen, Peer Grande, Merete Appleyard, and Børge G. Nordestgaard
Circulation 2005 112: 185-193. [Abstract] [Full Text]

Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease

Marcello Tonelli, Chris Isles, Timothy Craven, Andrew Tonkin, Marc A. Pfeffer, James Shepherd, Frank M. Sacks, Curt Furberg, Stuart M. Cobbe, John Simes, Malcolm West, Chris Packard, and Gary C. Curhan
Circulation 2005 112: 171-178. [Abstract] [Full Text]

Allogeneic Mesenchymal Stem Cell Transplantation in Postinfarcted Rat Myocardium: Short- and Long-Term Effects

Wangde Dai, Sharon L. Hale, Bradley J. Martin, Jin-Qiang Kuang, Joan S. Dow, Loren E. Wold, and Robert A. Kloner
Circulation 2005 112: 214-223. [Abstract] [Full Text]